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Abstract
Background: Frontotemporal lobar degeneration with ubiquitin and TDP-43 positive neuronal inclusions
represents a novel entity (FTLD-TDP) that may be associated with motor neuron disease (FTLD-MND); involvement
of extrapyramidal and other systems has also been reported.
Case presentation: We present three cases with similar clinical symptoms, including Parkinsonism, supranuclear
gaze palsy, visuospatial impairment and a behavioral variant of frontotemporal dementia, associated with either
clinically possible or definite MND. Neuropathological examination revealed hallmarks of FTLD-TDP with major
involvement of subcortical and, in particular, mesencephalic structures. These cases differed in onset and
progression of clinical manifestations as well as distribution of histopathological changes in the brain and spinal
cord. Two cases were sporadic, whereas the third case had a pathological variation in the progranulin gene 102
delC.
Conclusions: Association of a “progressive supranuclear palsy-like” syndrome with marked visuospatial impairment,
motor neuron disease and early behavioral disturbances may represent a clinically distinct phenotype of FTLD-TDP.
Our observations further support the concept that TDP-43 proteinopathies represent a spectrum of disorders,
where preferential localization of pathogenetic inclusions and neuronal cell loss defines clinical phenotypes ranging
from frontotemporal dementia with or without motor neuron disease, to corticobasal syndrome and to a
progressive supranuclear palsy-like syndrome.
Background
Amyotrophic lateral sclerosis (ALS) and frontotemporal
dementia (FTD) caused by frontotemporal lobar degen-
eration with ubiquitin and transactive response DNA
binding protein 43 (TDP-43) positive inclusions (FTLD-
TDP) represent two different manifestations of the same
neurodegenerative disease [1]. Distribution of TDP-43
related neuropathological changes include various
anatomical regions with differences in the predominance
of lesions, suggesting that TDP-43 proteinopathies
reflect the spectrum of a multisystem disorder [2-4].
Mutations in the progranulin (PGRN) gene, located on
chromosome 17, have been linked to inherited forms
associated with neuropathologically detectable TDP-43
proteinopathy and with different clinical symptomatol-
ogy [5-7]. Moreover, an increasing number of variations
within PGRN have been described http://www.molgen.
ua.ac.be/FTDMutations.
Progressive supranuclear palsy (PSP) is characterized
by early gait disturbances and falls, axial rigidity, vertical
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any medium, provided the original work is properly cited.gaze palsy, and subcortical dementia [8]. PSP is consid-
ered to be a tauopathy; however, a PSP-like syndrome
has been associated with ubiquitin-only-immunoreactive
neuronal changes [9], and thus could be part of the clin-
ical picture of “ALS-plus syndrome” caused by TDP-43
proteinopathy [2,10]. Moreover, FTLD-TDP may have a
presentation similar to corticobasal degeneration [11]
indicating that these disorders can present with a spec-
trum of clinical phenotypes that also overlaps other neu-
rodegenerative disorders.
Here we describe three cases, including one with a
variation in the PGRN gene, with a clinical presentation
reminiscent of PSP ("PSP-like syndrome”)i np a t i e n t s
with FTLD-TDP (with or without MND) that supports
the notion of a further, clinically distinguishable, pheno-
type within the spectrum of TDP-43 proteinopathies.
Clinical and neuropathological data were obtained
from three patients followed in the Departments of
Neurology, Thomayer Teaching Hospital and Motol
Teaching Hospital, Prague, CZ. Patients were assessed
using standardized diagnostic tools: magnetic resonance
(MRI), electromyography (EMG), routine blood analysis,
and neuropsychological assessments. All procedures
were explained to the patients and their caregivers, and
informed consent was obtained in all cases. All data
were analyzed with respect for patient privacy and the
protocol was approved by the Ethics Committee of Tho-
mayer Teaching Hospital.
During autopsy, formalin-fixed, paraffin-embedded
blocks were obtained from the following regions: frontal,
cingulate, temporal, parietal and occipital cortices and
subcortical white matter, basal ganglia, thalamus, hippo-
campus, cerebellum, and brainstem. For immunohisto-
chemistry 5 μm thick sections of formalin-fixed and
paraffin-embedded tissue were used with primary anti-
bodies against the following antigens: anti-tau AT8
(1:200, Pierce Biotechnology, Rockford, IL, USA, pS202/
pT205); ubiquitin (1:200, rabbit polyclonal; Dako,
Glostrup, Denmark); protein p62 (1:4,000, guinea pig
polyclonal; Progen Biotechnik GmbH, Heidelberg, Ger-
many); protein TDP-43 (1:2.000, mouse monoclonal;
Abnova Corp., Taipei, Taiwan, and 1:100, polyclonal;
P r o t e i n T e c hG r o u p ,C h i c a g o ,I l ,U S A ) ,a n dp h o s p h o -
TDP-43 (1:2.000, mouse monoclonal, pS409/410; Cosmo
Bio Co. Ltd, Tokyo, Japan). Semiquantitatively (0 = none;
1 = mild or few; 2 = moderate; 3 = severe or many), we
scored different types of inclusions in selected brain areas.
Genomic DNA was extracted from frozen bone marrow
samples (autopsy) using an isolating kit. The microtubule-
associated protein (MAPT) exon 1-10, transactive response
DNA binding protein (TARDBP) exons 2-6, progranulin
(PGRN) exons 0-12 and respective flanking intronic
regions were amplified as described previously. Products
were examined using agarose gel electrophoresis, treated
with ExoSAP-IT (USB, Cleveland, OH, USA), asymmetri-
cally amplified using the DTCS Quick Start Kit (Beckman
Coulter, Fullerton, CA, USA), and analyzed on a CEQ
8000 GeXP Genetic Analysis System (Beckman Coulter).
The resulting sequences were compared to published
TARDBP, MAPT, and PGRN sequences http://www.ncbi.
nlm.nih.gov.
Case presentation
Clinical data of the three patients are summarized in
(Table 1) and the temporal evolution of symptoms in
(Figure 1).
Case 1
A 70-year-old woman was referred to our department
for spontaneous ptosis and slowly (five months) progres-
sive dysarthria. In the family, apart from her two chil-
dren with multiple sclerosis, there was no history of
neurologic disease.
Clinical examination revealed asymmetric semiptosis,
paralytic dysarthria, and mild finger (right hand) weak-
ness. Reflexes were brisk and there was no sensory
impairment. Needle EMG showed chronic regeneration
and fibrillation patterns in the anterior tibialis and com-
mon finger extensor muscles. Nerve conduction studies
and repetitive stimulation were normal.
Gradually, disinhibition, emotional incontinence, and
spasmodic laughter developed. Five months later a
neurological examination revealed blepharospasm
instead of ptosis. Frontal lobe involvement (reduced
verbal fluency, stereotypias, perseverative features,
grasping, and apathy) became associated with impair-
ment in visuo-spatial functions and short-term mem-
ory. Akinesia with rigidity, but without tremor, was
more pronounced in axial muscles; reflexes remained
brisk. There was noticeable slowing of oculomotor sac-
cades, but without gaze palsy.
Over the next two months, the patient’s condition
progressively deteriorated. Extrapyramidal features and
dysexecutive signs worsened, accompanied by frequent
falls. The blepharospasm diminished and vertical gaze
palsy developed together with eye-lid closing apraxia.
Dysarthric features progressed and frontal-type gait
apraxia with astasia-abasia, and incontinence appeared.
A brain MRI showed marked asymmetric frontotem-
poral atrophy (Figure 2).
Neuropsychological assessment revealed relatively pre-
served episodic verbal memory and language, with con-
served learning abilities (Token Test and Boston
Naming Test). Executive functions were markedly
impaired (Wisconsin Card Sorting Test: one category,
more than 16 perseverative errors; Trail Making Test:
under 10
th percentile for age-matched norms). The
patient failed in immediate and delayed recall of the
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and copying were altered to a lesser degree.
Repeated EMGs, showing signs of widespread denerva-
tion and chronic reinervation, confirmed clinically definite
ALS, according to the El Escorial criteria [12]. Treatment
with riluzole was started, but with little effect on disease
evolution. Because of increased dysphagia and malnutri-
tion, a percutaneous endoscopic gastrostomy (PEG) was
performed six weeks later. The patient deceased two
months later from terminal bronchopneumonia.
Case 2
A 49-year-old woman, without comorbidities, was
referred for cognitive and behavioral changes. Two years
prior, her husband had noticed personality changes
accompanied by difficulties in complex task solving
(cooking, grooming). Her mood was slightly depressive
and apathetic; polydipsia had also been noticed by the
family (6 liters a day), but no metabolic or endocrine
abnormalities were found. There was a history of
dementia in the family involving a grandmother, who
died at the age of 92.
Six months later we observed gait instability, swallow-
ing difficulties and involuntary neck anteflexion. Asym-
metric, left-predominant, rigidity displaying the cogwheel
phenomenon and postural instability were present.
Reflexes were brisk. There was no gaze palsy or fascicula-
tions. MRI scans showed generalized atrophy with only
mild, nonspecific white matter changes (Figure 2).
The neuropsychological profile was primarily dysexe-
cutive (Frontal Assessment Battery, Digit Span, Verbal
Fluency Test, and Trail Making Test under 10
th percen-
tile for age-matched norms). Language analysis showed
mild alteration (Boston Naming Test 6 mistakes),
visuospatial functions were impaired (Clock Drawing
Test - incorrect placement and repeating of numbers,
Table 1 Summary of clinical presentations
Case 1 Case 2 Case 3
Age of onset 72 49 64
Duration (months) 18 25 29
Clinical appearance (syndrome) MND/PSP/FTLD FTLD FTLD/PSP
Central motoneuron dysfunction Hyperreflexia Generalized spasticity Right-sided spasticity
Periferal motoneuron
dysfunction
Yes, EMG proven Interosseal amyotrophy No
Dysarthria/dysphagia Yes, prominent Yes, later Yes-early/prominent
Early falls Yes Yes Yes
Eyelid opening apraxia Early Late Present
Oculomotoricity, conjugate
ocular pursuit movements
Abnormal/Voluntar movements reduced
both horisontally and vertically
Initially normal, reduced mainly vertically,
but after one year
Reduced mainly
vertically
Saccades Slow, hypometric Slow, hypometric Slow, hypometric
Bradykinesia Axial predominance Axial and limbs Axial predominance
Rigidity Axial predominance Axial and limbs Axial predominance
Tremor No No No
Dystonia No Facial movements, neck anteflexion and
lateroflexion
Late - retrocollis
Response to L-dopa Poor Poor Non
Executive dysfunction Prominent Prominent Prominent
Insight Lacking Present at the beginning Lacking
Frontal release signs Grasping/spastic laughter/disinhibited
behavior
Behavioral changes, dysexecutive syndrome Behavioral changes
Memory problems Minimal Minimal, effect of cueing Impaired
Visuospatial dysfunction Impaired Impaired Impaired
Gait apraxia Early feature Present early Early
Autonomic function N/A Not present Not present
Case 1 Case 2 Case 3
MRI Frontotemporal atrophy with left
predominance
Generalized atrophy with mild
predominance periventriculary and frontal
Frontotemporal and
brainstem atrophy
Cerebrospinal fluid Normal Not done Normal
EMG Probable ALS according to El Escorial
criteria, normal conduction
Not done Normal conduction, no
denervation
Pathological diagnosis FTLD-TDP/MND FTLD-TDP/MND FTLD-TDP/MND
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Page 3 of 11Rey-Osterrieth Complex Figure with respect to copy but
severely altered recall). We also noted important episo-
dic memory impairment with reduced learning abilities
sensible to cuing: The Auditory Verbal Learning Test
(AVLT): 16 words - 5 retrieved spontaneously, 11 more
with cuing) and occasional confabulations. The Mini
Mental State Examination (MMSE) score was 22/30.
Vertical gaze palsy appeared 10 months later, with
severe Parkinsonism and frequent falls. Levodopa (3 ×
62.5 mg/day) had no effect and was stopped after 1
month because of progressive dysphagia. The MMSE
dropped to 16/30 and the Activities of Daily Living
(ADL) scale revealed complete loss of functional capa-
city. Two months later, pseudobulbar signs with signifi-
cant dysphagia and weight loss (15 kg in 6 months) and
increasing spasticity with hyperreflexia and pyramidal
signs were reported. The patient received memantine
with no effect on MMSE or ADL, citalopram was added
to treat signs of mild depression.
Two months later (after nearly two years of evolution),
her condition deteriorated rapidly to profound dementia
and severe Parkinsonism. Interosseal muscle atrophy
was found, but no fasciculations; reflexes remained
brisk. An EMG was scheduled but never completed.
Figure 1 Temporal evolution of symptoms and features. Bold lines at the end of the horizontal time line indicate deceases.
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her condition, she died of bronchopneumonia and septic
shock.
Case 3
A 64-year-old woman, with a family history of stroke
(mother), developed gait instability, dysarthria, and
mnestic difficulties over a 2 year period. Muscle rigidity
appeared, falls occurred, and she became incontinent.
Six months later, in another hospital, multiple system
atrophy was diagnosed, and treatment with levodopa
and pramipexole was started. Escitalopram was added
for depression a few months later. Despite increasing
doses of levodopa (up to 1000 mg daily), rigidity and
akinesia worsened and the patient became wheelchair-
bound. Ultimately, she was referred for diagnostic re-
evaluation.
Clinical examination found psychomotor slowing, dys-
executive features with apathy, perseverations, and
stereotypical behavior. Verbal fluency was decreased and
there was a marked lack of insight. Speech required
effort and was associated with palilalia and fluctuating
dysphagia. There was no gaze paralysis, but horizontal
and vertical saccades were slowed; fixation was impaired
and eyelid-opening apraxia was observed. Extrapyrami-
dal features included extensive axial rigidity with signifi-
cant akinesia, but no tremor. Notable right-sided
hypertonus was associated with extremity spasticity.
A MRI revealed significant atrophy with frontal and
temporal predominance, and periventricular dilatation,
and brain stem atrophy (Figure 2). The EMG was diffi-
cult to evaluate (extensive rigidity and lack of coopera-
tion); there was suspicion of denervation potentials.
A cognitive assessment was incomplete due to lack of
cooperation. However, we found signs of noticeably
impaired executive functions and behavioral changes,
visuo-constructional abilities and episodic memory were
impaired with relatively conserved cueing effect (figure
copying, cued recall).
Despite high-doses of L-dopa (1.5 g daily) and baclo-
fen (150 mg daily) the condition worsened over the next
months. Subcortical dementia with severely impaired
fluency progressed to anarthria, and finally mutism.
Massive perseveration interfered with any spontaneous
movement and spasticity increased to flexion contrac-
tures. Oculomotor involvement included gaze apraxia,
dissociation between impaired voluntary gaze and pre-
served involuntary horizontal pursuit, together with a
freely elicitable oculocephalic reflex. Rigidity and akine-
sia remained notable in axial regions, later accompanied
by dystonia and retrocollis. The patient’s condition con-
tinued to decline and she deceased shortly thereafter
from urosepsis.
Genetic analysis revealed a pathogenic mutation (102
delC (predicted protein: Gly35GlufsX19)) in the PGRN
gene previously described [3]. We found no variations in
TARDBP and MAPT genes.
Neuropathology
Neuronal loss and gliosis were most prominent in the
mesencephalon, basal ganglia, and frontal and temporal
cortices. TDP-43 and phospho-TDP-43 immunostaining
revealed neuronal cytoplasmic inclusions of different
types, including compact globular and dot-like struc-
tures, more pathological profiles were detected using
anti-phospho-TDP-43 antibody. Neuritic profiles,
Figure 2 Magnetic resonance images. MRI show an asymmetric frontotemporal atrophy on transversal scans in case 1 (left, FLAIR sequence),
case 2 (middle, T2 sequence), and case 3 (right, FLAIR sequence). In inboxes a relatively preserved brain stem is demonstrated on sagittal
sections.
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seen in different brain structures (Figure 3). Glial cyto-
plasmic inclusions and thread-like (phospho)-TDP-43
immunoreactivity was seen in the white matter. These
cases did not strictly fit the subtyping schemes recently
proposed [13]. However, due to the slight predominance
of neuronal cytoplasmic inclusions in the frontal cortex
and hippocampus Case 1 and 2 were reminiscent, fol-
lowing the proposed classification, of type 2. The long
a n dt o r t u o u sn e u r i t e sa sw e l la sn e u r o n a lc y t o p l a s m i c
inclusions, seen in Case 3, made it more compatible
with type 3 according to Cairns et al. [14]. Neuronal
nuclear inclusions, associated with type 4, were not con-
vincingly observed in any of cases. In addition skein-like
neuronal inclusions were seen in brainstem nuclei in all
cases, including substantia nigra (all), hypoglossal
nucleus (Cases 1 and 2) and inferior olivary nucleus
(Case 3).
In summary, we found hallmarks of FTLD-MND with
ubiquitin-immunoreactive neuronal changes and intracy-
toplasmic and neuritic TDP-43, phosphorylated TDP-43,
and p62 immunopositivity (Figure 3) compatible with
the diagnosis of FTLD-TDP with MND. Detailed map-
ping of immunohistochemical positivity in different
brain areas is summarized in (Figure 4).
Conclusions
We present three autopsy proven cases of FTLD-TDP
with clinical manifestation as “progressive supranuclear
palsy plus” syndrome. A summary of our study observa-
tions include: (i) during the clinical course, but not as
initial symptoms, all patients showed clinical hallmarks
of PSP (subcortical dementia, axial predominant akinesia
and rigidity, supranuclear gaze abnormalities, and fre-
quent falls), (ii) additionally, upper and/or lower motor
neuron involvement and a frontal behavioral syndrome
Figure 3 Immunohistochemistry for phospho-TDP-43. Spherical, “Lewy-like” and skein-like neuronal cytoplasmic inclusions as well as diffuse
granular inclusions were found in substantia nigra (case III - A), pontine base (case I - B) and in hypoglossal nucleus (case II - C); thin and long
as well as globular neurites in hippocampal formation (case I - D). Scale bars = Bar graphs: 50 μm (A), 100 μm (B and D), 200 μm (C).
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TDP was confirmed neuropathologically in all cases, (iv)
mutations in MAPT, TARDBP were not observed, while
in one patient we found a PGRN mutation (Case 3), and
(v) the extent of histopathological changes correlated
positively with progression and were widespread in sub-
cortical structures.
All cases shared some common features, although
there were also some important differences (Table 1,
Figure 1 and 2).
Figure 4 Distribution of pathological changes within the brain tissue. Evaluation: (*) mild, (**) moderate and (***) high presence of a given
pathological feature. NC - neuronal cells, NCI - neuronal cell inclusions, Gran-Dentate Gyrus - dentate gyrus, granular layer.
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the first year. Frontal lobe involvement with behavioral
changes and a “PSP-like” syndrome with Parkinsonism
and supranuclear ophthalmoplegia developed only later.
Illness duration was 14 months. Neuronal inclusions
were common in the hippocampal and temporal areas,
caudate nucleus, thalamus, and oculomotor complex,
and in the inferior olive, while TDP-43 immunoreactive
neurites and glial inclusions and neuronal loss was pro-
minent in the caudate nucleus, locus coeruleus, substan-
tia nigra, and oculomotor nuclei. Skein-like inclusions
were detected in the hypoglossal nucleus.
In contrast, the “PSP-like” syndrome in Case 2
appeared earlier, was associated with behavioral signs of
FTD and Parkinsonism, progressed slowly to dementia
and severe rigidity with supranuclear gaze palsy. The
clinical course was longer (4 years) and lower motor
neuron signs came very late. Neuronal inclusions
(including skein-like neurites and glial pathology) were
more widespread and strongly associated with subcorti-
cal and brainstem nuclei.
Case 3 had a clinical picture that was most typical for
PSP, linked to FTD and upper motor neuron involve-
ment. Neuronal inclusions and neurites and glial inclu-
sions had dispositions similar to Case 2 (hippocampal
areas, fronto-temporal cortex, caudate, putamen, sub-
stantia nigra). A pathogenic mutation (102 delC) in the
PGRN gene was also detected.
Clinical manifestations, age of onset, duration of ill-
ness and distribution of neuropathological changes of
PGRN gene mutation carriers are variable: the majority
have progressive aphasia or frontotemporal dementia,
but without symptoms of MND or PSP [13,15]. Familial
forms of FTLD expressing prominent parkinsonian fea-
tures have been linked to mutations in MAPT, formerly
frontotemporal dementia and Parkinsonism linked to
chromosome 17 (FTDP-17) [16]. We did not observe
tau pathology and MAPT gene analysis excluded muta-
tions in all presented cases. More recently, MAPT nega-
tive cases with a familial setting were shown to harbor
mutations in the PGRN gene [17]. These cases were
neuropathologically identified as tau negative but ubi-
quitin-positive [5,18]. The clinical and neuropathological
phenotype and age of disease onset, tends to be highly
variable not only among families but even between indi-
viduals in one family [19]. Case 3 expands this group to
include the PSP-like phenotype, in addition to primary
progressive aphasia [20] or corticobasal syndrome [21].
In summary, criteria for probable PSP [8] were ful-
filled in Cases 1 and 2 (Table 1). In Case 3, all signs
were present, but the evolution lasted more than one
year. Overall, features of PSP developed later in the
course of our patients. It must be noted that none were
diagnosed clinically as PSP. The severe frontal and
temporal atrophy on MRI (Figure 2) was oriented more
towards FTLD; however all displayed considerable fea-
tures of PSP. It is noteworthy, that in addition to sub-
cortical dementia, typical for PSP [22], all of our
patients developed considerable behavioral and person-
ality changes compatible with behavioral variants of
FTD. This becomes most apparent in Case 3 (apathy,
perseverations, stereotypical behavior, lack of insight
and dynamic aphasia), however, rigidity, oculomotor
findings, considerably restricted verbal fluency and the
absence of disinhibition or compulsivity are less typical
of FTD. MRI scans of our patients showed only mild
asymmetry of atrophy and the degree of frontal and
temporal atrophy was not as impressive as in many
other FTLD-TDP-43 cases. The subcortical white matter
changes in Case 3 are similar to findings in PGRN
mutation carriers [23]. Finally, MRIs in our patients did
not show posterior fossa findings evoking PSP (such as
hummingbird sing, thinning of superior cerebellar ped-
uncle or prominent mesencephalic atrophy).
All patients corresponded to possible/probable MND
with significant upper motor neuron signs in Case 3,
lower motor neuron involvement in Case 2, and both in
Case 1 [12]. The extent of histopathological changes
(Figure 4) correlated positively with progression.
The distribution of histopathological changes in particu-
lar TDP-43 immunoreactive profiles involved subcortical
and brainstem structures somewhat more than reported
previously, in association with FTLD-TDP subtypes [24],
supporting the notion that TDP-43 proteinopathies are
representatives of a multisystem proteinopathy [25] with
involvement of anatomical regions corresponding to pre-
dominant clinical symptoms. The progression rate of clini-
cal features differed in our cases (Figure 1).
An important finding in our patients is the impair-
ment of visuospatial functions in all three cases. This
profile is rather uncommon in parkinsonian syndromes.
A large prospective cohort of patients with PSP and
multiple system atrophy (MSA) demonstrated the exis-
tence of a cognitive profile similar to that previously
reported in idiopathic Parkinson´s disease. Visuospatial
functions scores, measured on the dementia rating scale
(DRS), for construction and conceptualization, were lar-
gely preserved [26]. Another study suggested that
visuospatial functions are not consistently impaired in
atypical parkinsonian syndromes, but the degree and
pattern varied across the diseases. This could imply a
different neural basis in each condition, since the most
prominent visuospatial impairment was linked to corti-
cobasal degeneration [27]. There are other findings how-
ever, which suggest that visuospatial and visuoperceptual
dysfunctions reflect structural grey matter changes in
temporo-parietal cortical regions of Parkinson´s disease
patients [28].
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of motor neuron disease. Patients with FTLD-MND and
ubiquitin inclusions whose visuospatial skills were tested
by copying drawings and the visual object and space
perception battery (VOSP) subtests, did not show
remarkable alterations [29].
On the other hand, visuospatial deficits have been
reported in FTLD patients. Koedam et al. recently pub-
lished a very interesting observation; neuropsychological
profiles, including visuospatial impairment, does not dif-
fer between frontotemporal dementia patients with and
without lobar atrophy, although patients without atro-
phy, on MRI, were less severely demented [30]. Other
authors have suggested that parietal deficits including
visuospatial dysfunction may be a prominent feature of
PGRN mutations [31].
A very similar observation to ours demonstrated a
movement disorder resembling PSP and associated with
dementia and MND-like pathology. Besides selective
verbal and action processing, there was visual recall and
recognition (Door and People test (DPT)) and lower
construction and conceptualization scores (VOSP). The
most important neuropathological findings were abun-
dant ubiquitin-positive inclusions, which were also
detected in areas without apparent atrophy or neuronal
loss [32].
There have been only very limited reports of oculomo-
tor abnormalities in FTLD-MND. In our cases we found
significant neuropathological changes in the mesence-
phalic tegmentum. This supports the notion that vulner-
ability patterns may differ inT D P - 4 3p r o t e i n o p a t h i e s
(sporadic and genetic forms) leading to variable clinical
phenotypes. Indeed, our observations with several pre-
vious studies indicate that sporadic TDP-43 proteinopa-
thies may present as MND, FTD, progressive aphasia,
FTD with MND, corticobasal syndrome [11], and PSP-
like phenotypes associated with FTD and features of
MND. These clinical phenotypes may show overlap with
tauopathies; indeed PSP (tauopathy) may be also asso-
ciated with MND and corticospinal tract degeneration
[33]. Furthermore, these clinical phenotypes were
reported in cases with an established genetic cause,
linked not only to PGRN mutations but also to muta-
tions in TARDBP.M N D ,F T L D - M N D ,a n dF T Dw i t h
supranuclear palsy having also been associated with
TARDBP variations [34-36], demonstrating the complex-
ity of clinico-pathological and genetic relations.
In conclusion, our observation suggests that: (i) asso-
ciation of “PSP-like” to “ALS-plus” syndromes in the
same patient may represent a clinically distinguishable
entity within a broad spectrum of TDP-43 positive neu-
rodegeneration; (ii) this clinical manifestation develops
irrespective of genetic variation in TARDBP, MAPT, and
PGRN;( iii) the clinical picture seems to be related to
preferential localization of pathogenetic inclusions and
neuronal cell loss rather than specific pathological
mechanisms of the disease itself; and (iv) motor neuron
involvement, visuospatial and frontal behavioral signs
should be systematically explored in atypical PSP
patients.
Consent
Written informed consent was obtained in one case
from the patient and in two cases from patient´s rela-
tives for publication of this case report and any accom-
panying images. A copy of the written consent is
available for review by the Editor-in-Chief of this
journal.
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